Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mean decrease » a decrease (Expand Search)
0 decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
05 0 » 0 0 (Expand Search), 01 0 (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mean decrease » a decrease (Expand Search)
0 decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
05 0 » 0 0 (Expand Search), 01 0 (Expand Search)
-
21
OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts.
Published 2019“…However, co-treatment of OCA with Gemcitabine or Cisplatin resulted in a tumor volume significantly lower compared to Gemcitabine or Cisplatin alone (p < 0.05). Means ± SE of N = 5 for each group. * p < 0.05 vs controls, <sup>&</sup> p < 0.05 vs OCA, <sup>¤</sup> p < 0.05 vs Cisplatin alone, <sup>§</sup> p < 0.05 vs Gemcitabine alone. …”
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis
Published 2016“…On patiromer, P decreased from 7.0 ± 0.5 to 6.2 ± 0.5 mg/dl (p = 0.04). …”
-
30
-
31
-
32
Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB.
Published 2013“…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR.
Published 2024Subjects: